Abstract: Mobile management method, system and client. Method includes receiving a DNS query for a host name from an application on client; retrieving reputation data associated with host name from a local cache on client; and determining a policy based on host name and the reputation data. Based on determined policy for the host name, blocking attempted network flows to a host corresponding to host name to produce blocked attempted network flows. Method also includes sending attempted network flow metadata related to the blocked attempted network flows to a collector on client; transmitting the attempted network flow metadata from the collector to a VPN server pool via a VPN tunnel; and producing an anomaly report from the transmitted attempted network flow metadata. The anomaly report includes at least one of anomalies, cohorts, trends, location boundaries, detected network security issues, detected compromised clients and/or optimized network usage.

Abstract: An internal container for storage of a first substance and in use with an external container for storage of a second disparate substance is provided. The internal container may be stored within the external container while keeping the first substance and the second substance separated until a predetermined time. At the predetermined time the first substance and the second substance may be mixed by continuously accelerating or shaking the external container without any direct user contact with the internal container.

Abstract: The present invention relates, inter alia, to a method of preventing or treating skin cancer or skin precancer, the method comprising locally administering to the skin of a subject in need thereof an effective amount of a compound of Formula (I) or a pro-drug thereof, Formula (I) wherein the subject is being administered an immunosuppressant agent that binds to FKBP12. The agent that binds to FKBP12 may be tacrolimus. The invention also relates to methods of preventing or treating a skin condition, disorder or disease associated with administration of an immunosuppressant agent that binds to FKBP12, and to uses of the compound of Formula (I) in treating skin cancer or skin precancer, or a skin condition, disorder or disease associated with administration of an immunosuppressant agent that binds to FKBP12.

Abstract: The present invention relates generally to medical devices, systems, and methods for use in surgery. In particular, the disclosed system and methods relate to an intervertebral spinal implant sized and dimensioned for the lumbar spine implantable via a posterior approach. The system includes an implant, instruments for delivering the implant.

Abstract: A mechanical vacuum dressing comprising: a first valve layer comprising a first one-way valve; a second valve layer comprising a second one-way valve; the first valve layer being joined to the second valve layer so as to define a chamber therebetween; the first one-way valve being configured to admit fluid into the chamber through the first one-way valve but prevent fluid from exiting the chamber through the first one-way valve; the second one-way valve being configured to exhaust fluid from the chamber through the second one-way valve but prevent fluid from entering the chamber through the second one-way valve; and the second valve layer comprising an elastomeric material such that (i) when the second valve layer is moved away from the first valve layer, the volume of the chamber is increased, and (ii) when the second valve layer is thereafter released, the second valve layer moves back towards the first valve layer and the volume of the chamber is decreased.

Abstract: The present invention relates generally to medical devices, systems, and methods for use in surgery. In particular, the disclosed system and methods relate to an intervertebral spinal implant sized and dimensioned for the lumbar spine implantable via a posterior approach. The system includes an implant, instruments for delivering the implant.

Abstract: A mechanical vacuum dressing comprising: a first valve layer comprising a first one-way valve; a second valve layer comprising a second one-way valve; the first valve layer being joined to the second valve layer so as to define a chamber therebetween; the first one-way valve being configured to admit fluid into the chamber through the first one-way valve but prevent fluid from exiting the chamber through the first one-way valve; the second one-way valve being configured to exhaust fluid from the chamber through the second one-way valve but prevent fluid from entering the chamber through the second one-way valve; and the second valve layer comprising an elastomeric material such that (i) when the second valve layer is moved away from the first valve layer, the volume of the chamber is increased, and (ii) when the second valve layer is thereafter released, the second valve layer moves back towards the first valve layer and the volume of the chamber is decreased.

Abstract: A mechanical vacuum dressing comprising: a first valve layer comprising a first one-way valve; a second valve layer comprising a second one-way valve; the first valve layer being joined to the second valve layer so as to define a chamber therebetween; the first one-way valve being configured to admit fluid into the chamber through the first one-way valve but prevent fluid from exiting the chamber through the first one-way valve; the second one-way valve being configured to exhaust fluid from the chamber through the second one-way valve but prevent fluid from entering the chamber through the second one-way valve; and the second valve layer comprising an elastomeric material such that (i) when the second valve layer is moved away from the first valve layer, the volume of the chamber is increased, and (ii) when the second valve layer is thereafter released, the second valve layer moves back towards the first valve layer and the volume of the chamber is decreased.

Abstract: A method of forming tailored cast blanks including determining at least one of a thickness pattern or profile pattern for a blank, generating a layout for a series of blanks having the determined thickness or profile pattern and casting a strip in accordance with the layout, including varying the caster width during casting of the strip.

Abstract: The present invention relates generally to medical devices, systems, and methods for use in surgery. In particular, the disclosed system and methods relate to an intervertebral spinal implant sized and dimensioned for the lumbar spine implantable via a posterior approach. The system includes an implant, instruments for delivering the implant.

Abstract: The present invention relates generally to medical devices, systems, and methods for use in surgery. In particular, the disclosed system and methods relate to an intervertebral spinal implant sized and dimensioned for the lumbar spine implantable via a posterior approach. The system includes an implant, instruments for delivering the implant.

Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.

Abstract: The present invention relates generally to medical devices, systems, and methods for use in surgery. In particular, the disclosed system and methods relate to an intervertebral spinal implant sized and dimensioned for the lumbar spine implantable via a posterior approach. The system includes an implant, instruments for delivering the implant.

Abstract: Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein “RIa”, “RIb”, “RIc”, “RId”, “RIe”, are defined herein above, which compounds are believed suitable for use in positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR) receptors, for example, those found in the cerebral cortex and the hippocampus. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Alzheimer's disease (AD), schizophrenia, and Parkinson's disease (PD), or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.

Abstract: The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of ?7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.

Abstract: The present invention relates generally to medical devices, systems, and methods for use in surgery. In particular, the disclosed system and methods relate to an intervertebral spinal implant sized and dimensioned for the lumbar spine implantable via a posterior approach. The system includes an implant, instruments for delivering the implant.

Abstract: The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of ?7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.

Abstract: The invention comprises systems and devices for calculating and displaying real-time race information to a racer during a race. A portable race device may be worn by a racer. During the race, while within range of a race gate transmission, the race device receives gate crossing times for other race participants, and may calculate and display the current positions and times for a selected race group, and the pace needed for the racer to win, and also may display the projected finish positions and times for a selected race group, and the pace needed for the racer to win.

Abstract: Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein “RIa”, “RIb”, “RIc”, “RId”, “RIe”, are defined herein above, which compounds are believed suitable for use in positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR) receptors, for example, those found in the cerebral cortex and the hippocampus. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Alzheimer's disease (AD), schizophrenia, and Parkinson's disease (PD), or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.